麦格理发表报告指，创科实业上半年收入同比增长6%至82.92亿美元，略超该行及市场预期介乎0.6%至0.7%；纯利同比增长17.5%至7.38亿美元，较该行及市场预期各高出3%；毛利率同比扩张2.6个百分点至42.9%，较该行预期高出1.8个百分点，主要受关税缓解措施持续、产品及地区组合有利，以及生产效率持续提升所带动。公司重申核心业务收入展望，并对达成或超越2027年10%的经营利润率目标更具信心。考虑到上半年业绩优于预期及对终端市场前景更趋正面，麦格理上调创科2026及2027年纯利预测分别1%及2%，目标价由154港元上调2%至157港元，相当于2027年预测市盈率20倍，维持“跑赢大市”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.